Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?
5-Loxin is a compound extracted from an ancient herb that might be considered as a potent lipooxygenase inhibitor. The results observed in a preliminary trial suggest a highly intriguing clinically relevant symptomatic effect contrasting with a poor bioavailability of this compound. Moreover, in this trial, a statistically significant decrease in matrix metalloproteinase enzyme serum level suggests that, in addition to the observed symptomatic effect, such a compound might have a disease modifying effect in osteoarthritis. Further studies are required both to confirm the symptomatic efficacy and acceptable safety profile and to evaluate the potential chondromodulating effect of this compound.
Dougados
Maxime
M
D006801:Humans; D016859:Lipoxygenase Inhibitors / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
D016859:Lipoxygenase Inhibitors